drugset / Trial / NCT01019369

Study of Self or Clinic Administration of DepoProvera

NCT01019369

RandomizedParallel-groupOpen-labelPrevention

Summary

Depot medroxyprogesterone acetate (DepoProvera) is an acceptable form of contraception for many women. However, difficulty in access may cause many women to discontinue use, often without the use of another effective method of contraception, thereby leaving them vulnerable to unintended pregnancy. This study will randomly assign women who present for contraceptive services to two groups: self or clinic administered SC DMPA. The participants will be followed for one year to compare continuation rates, acceptability, cost effectiveness, evidence of skin changes, and need for continued support between the two groups.

Timeline

Start
2010-03
Primary completion
2011-01
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator medroxyprogesterone acetate Other / unclassified 104 mg Subcutaneous

Indications

No indication recorded.